文献速递消化道肿瘤与早癌

荟萃分析:需胃酸抑制患者使用质子泵抑制剂与胃癌风险

Meta-analysis: Use of proton pump inhibitors and risk of gastric cancer in patients requiring gastric acid suppression.
PubMed 文献 · Aliment Pharmacol Ther · 2022-12-31

为评估质子泵抑制剂(PPI)与胃癌风险的关系,该系统检索截至2022年6月1日的随机和非随机研究,以H2受体拮抗剂使用者为对照。固定效应RR=1.05,0.98-1.12),证据确定性低。

要点

  • 对混杂充分调整的非随机研究未发现PPI与胃癌存在关联,证据确定性低。
  • 随机证据极不精确,提供极低确定性证据。
  • 未发现令人信服的剂量反应或长期使用风险增加的证据。

核心结论

  • 在充分控制混杂的非随机研究中,未发现PPI与胃癌存在关联。
  • 已发表研究可能存在残余混杂。

研究设计与样本

  • 系统检索Medline/PubMed、Embase和Scopus数据库(截至2022年6月1日)的随机和非随机研究。
  • 纳入以H2受体拮抗剂使用者为对照、评估PPI与胃癌关联的研究。
  • 采用随机效应和固定效应模型计算汇总估计值,使用GRADE评估证据确定性。

主要发现

  • 随机证据极不精确,提供极低确定性证据。
  • 未发现令人信服的剂量反应或长期使用风险增加的证据。
  • 缺乏或极少调整混杂与更大的效应量相关。

关键数值与推荐

  • 随机临床试验证据极不精确,证据确定性极低。

临床怎么用

  • 原文未据此给出推荐。
  • 在充分控制混杂的非随机研究中未发现PPI与胃癌关联。

局限性

  • 已发表研究可能存在残余混杂。
  • 随机证据极不精确,提供极低确定性证据。
  • 对混杂充分调整的非随机研究证据确定性低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Proton-pump inhibitors (PPIs) are suspected to increase the risk of gastric cancer. AIM: To assess the risk of gastric cancer associated with the use of PPIs. METHODS: We systematically searched Medline/PubMed, Embase and Scopus databases (until June 1, 2022) for randomised and non-randomised studies (NRS) of the association between PPIs and gastric cancer having considered Histamine-2 receptor antagonists (H2RAs) users as controls. We chose this comparison to minimise confounding by indication, and focus on patients requiring gastric acid suppression. Two authors independently extracted study data and assessed each study's risk of bias. Maximally-adjusted relative risk (RR) estimates were extracted. Heterogeneity and small-study effect were examined, and summary estimates were calculated using random- and fixed-effect models. Stratified analyses and meta-regression were employed to explore heterogeneity. We used GRADE to evaluate the certainty of evidence. RESULTS: Of 8375 records, 12 NRS (>6 million patients; 11,554 gastric cancers) and two randomised clinical trials (498 patients; 1 gastric cancer) fulfilled the eligibility criteria. Randomised evidence was very imprecise and provided very-low certainty evidence. Meta-analysis of six NRS providing a comprehensive adjustment for confounding (2.5 million patients; 7372 gastric cancers) did not show any association between PPIs and gastric cancer (RRrandom = 1.07, 0.97-1.19; RRfixed = 1.05, 0.98-1.12). The certainty of the evidence was low. No convincing evidence of dose-response, or increased risk with long-term use, was found. Lack of or minimal adjustment for confounding was associated with larger effect sizes. CONCLUSIONS: We found no association between PPIs and gastric cancer in NRS having adequately controlled for confounding. Published studies may suffer residual confounding. SYSTEMATIC REVIEW REGISTRATION: CRD42022335971.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Piovani D, Tsantes AG, Schünemann HJ, et al. Meta-analysis: Use of proton pump inhibitors and risk of gastric cancer in patients requiring gastric acid suppression. Aliment Pharmacol Ther. 2022. PMID: 36585832. doi:10.1111/apt.17360

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。